n a landmark development for global cancer care, Cipla Limited (BSE: 500087; NSE: CIPLA EQ), a leading global pharmaceutical company, today announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for